drug
as of 2026-07-01Sarcosine
Sarcosine (N-methylglycine)sarcosinesarcosine+ BESarcosine and D-serine
MeSH D012521
at a glance
DIETARY_SUPPLEMENT
Pre-approval / investigational in the US
Developed by China Medical University Hospital
6 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
DIETARY_SUPPLEMENT
Indications
Investigational (via trials)
Trials
6
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia
NCT01503359Phase 2Completed
Treatment of N-methyl-D-aspartate (NMDA) Enhancers for Schizophrenia
NCT01047592Phase 2Completed
A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia
NCT00538070—Completed
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
NCT00328276Phase 2Completed
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
NCT00276263Phase 2Withdrawn
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
NCT00491569Phase 2Completed
KOLs & investigators
9
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
trial
indication
KOL
Dominik Strzelecki, MD, PhD
personKOL score 8
Marc L. Steinberg, PH.D.
personKOL score 5
Hsien-Yuan Lane, MD.PhD.
personKOL score 5
Bernard A Fischer, M.D.
personKOL score 5